Accueil>>Analytical Standards>>AGN 193109-d7

AGN 193109-d7

Catalog No.GC46817

AGN 193109-d7 est l'AGN 193109 marqué au deutérium. AGN 193109 est un analogue de rétinoÏde et agit comme un antagoniste spécifique et très efficace des récepteurs de l'acide rétinoÏque (RAR), avec des Kd de 2 nM, 2 nM et 3 nM pour RARα ; , RARβ, et RARγ, respectivement.

Products are for research use only. Not for human use. We do not sell to patients.

AGN 193109-d7 Chemical Structure

Cas No.: 1216429-25-2

Taille Prix Stock Qté
1 mg
556,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AGN 193109-d7 is intended for use as an internal standard for the quantification of AGN 193109 by GC- or LC-MS. AGN 193109 is an antagonist of retinoic acid receptors (RARs).1 AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. In vivo, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.2

1.Agarwal, C., Chandraratna, A.S., Johnson, A.L., et al.AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cellsJ. Biol. Chem.271(21)12209-12212(1996) 2.Kochhar, D.M., Jiang, H., Penner, J.D., et al.The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental eventsInt. J. Dev. Biol.42(4)601-608(1998)

Avis

Review for AGN 193109-d7

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AGN 193109-d7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.